PI3K/AKT and MAPK1 molecular changes preceding matrix metallopeptidases overexpression during tamoxifen-resistance development are correlated to poor prognosis in breast cancer patients
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
PI3K/AKT and MAPK1 molecular changes preceding matrix metallopeptidases overexpression during tamoxifen-resistance development are correlated to poor prognosis in breast cancer patients
Authors
Keywords
-
Journal
Breast Cancer
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-08-10
DOI
10.1007/s12282-021-01277-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Tissue inhibitor of metalloproteinase-1 (TIMP-1) as a prognostic biomarker in gastrointestinal cancer: a meta-analysis
- (2021) Lili Qin et al. PeerJ
- Elevated MMP9 expression in breast cancer is a predictor of shorter patient survival
- (2020) Chitra Joseph et al. BREAST CANCER RESEARCH AND TREATMENT
- The NFκB Pathway Promotes Tamoxifen Tolerance and Disease Recurrence in Estrogen Receptor–Positive Breast Cancers
- (2020) Irida Kastrati et al. MOLECULAR CANCER RESEARCH
- Upregulation of PI3K/AKT/PTEN pathway is correlated with glucose and glutamine metabolic dysfunction during tamoxifen resistance development in MCF-7 cells
- (2020) Lama Hamadneh et al. Scientific Reports
- Breast Cancer Treatment
- (2019) Adrienne G. Waks et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Metalloproteinases and their Roles in Human Cancer
- (2019) Roopali Roy et al. Anatomical Record-Advances in Integrative Anatomy and Evolutionary Biology
- Pathways to Endocrine Therapy Resistance in Breast Cancer
- (2019) Md. Moquitul Haque et al. Frontiers in Endocrinology
- Overcoming endocrine resistance in hormone receptor–positive breast cancer
- (2018) A. AlFakeeh et al. Current Oncology
- Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment
- (2018) Hitisha K. Patel et al. PHARMACOLOGY & THERAPEUTICS
- A systematic review of interventions to improve adherence to endocrine therapy
- (2018) Sue P. Heiney et al. BREAST CANCER RESEARCH AND TREATMENT
- Oldenlandia diffusa suppresses metastatic potential through inhibiting matrix metalloproteinase-9 and intercellular adhesion molecule-1 expression via p38 and ERK1/2 MAPK pathways and induces apoptosis in human breast cancer MCF-7 cells
- (2017) Tae-Wook Chung et al. JOURNAL OF ETHNOPHARMACOLOGY
- Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative breast cancer
- (2017) Kazuhiro Araki et al. Breast Cancer
- MMP1 expression is activated by Slug and enhances multi-drug resistance (MDR) in breast cancer
- (2017) Ching-Ju Shen et al. PLoS One
- Knockdown of RHOC by shRNA suppresses invasion and migration of cholangiocellular carcinoma cells via inhibition of MMP2, MMP3, MMP9 and epithelial-mesenchymal transition
- (2016) HAIXIA YANG et al. Molecular Medicine Reports
- Lunasin suppresses the migration and invasion of breast cancer cells by inhibiting matrix metalloproteinase-2/-9 via the FAK/Akt/ERK and NF-κB signaling pathways
- (2016) QIANQIAN JIANG et al. ONCOLOGY REPORTS
- The role of TIMPs in regulation of extracellular matrix proteolysis
- (2015) Valerie Arpino et al. MATRIX BIOLOGY
- A new role for the PI3K/Akt signaling pathway in the epithelial-mesenchymal transition
- (2015) Wenting Xu et al. Cell Adhesion & Migration
- TIMP-1 Increases Expression and Phosphorylation of Proteins Associated with Drug Resistance in Breast Cancer Cells
- (2013) Omid Hekmat et al. JOURNAL OF PROTEOME RESEARCH
- Diverse evolutionary paths to cell adhesion
- (2010) Monika Abedin et al. TRENDS IN CELL BIOLOGY
- An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients
- (2009) Balazs Györffy et al. BREAST CANCER RESEARCH AND TREATMENT
- Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer
- (2009) Maggie C. U. Cheang et al. JNCI-Journal of the National Cancer Institute
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started